STROBE diagram showing construction of the cohorts.

DLB, dementia with Lewy bodies; AChEIs, acetylcholinesterase inhibitors; LBD, Lewy body disease; DLB, dementia with Lewy body; CPFT, Cambridgeshire and Peterborough NHS Foundation Trust; ICD-10, World Health Organization International Statistical Classification of Diseases and Related Health Problems, 10th revision.</p

Patient characteristics at baseline.

Patient characteristics at baseline.</p

Strengthening the reporting of observational studies in epidemiology (STROBE) checklist.

(DOCX)</p

Additional information on study methods and findings.

(DOCX)</p

Kaplan-Meier survival curves of admissions and mortality in patients with dementia with Lewy bodies, by medication use.

Panels A, B and C present the recurrent events. P values are calculated from the log-rank test. AChEIs, acetylcholinesterase inhibitors.</p

Association of antidementia medication use with risk of admission, length of stay, and risk of death among patients with dementia with Lewy bodies.

Hazard ratios (HR), 95% confidence intervals (CI), and p values were estimated from Cox proportional hazards models. Coefficients, 95% confidence intervals (CI), and p values were estimated from linear regression. Adjusted HRs/coefficients were adjusted for age, sex, marital status, ethnicity, socio-economic status (Index of Multiple Deprivation), antipsychotic use, antidepressant use, cognitive status/score, physical comorbidity, anticholinergic burden, and global health performance. The blue lines show the unadjusted HRs/coefficients, the red lines show the adjusted ones, and the grey dotted line shows the cut-off for negative or positive associations (0 for coefficients and 1 for hazard ratios). AChEIs, acetylcholinesterase inhibitors.</p